all report title image
  • To Be Published : Apr 2024
  • Code : CMI236
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Cystic fibrosis (CF) is a genetic disorder that usually affects the lungs and may also affect the pancreas, kidneys, liver, and intestine. Long-term repercussions including difficulty in breathing and coughing as a result of recurrent lung infections can be seen in CF. Some of the other signs and symptoms include sinus infections, poor growth, infertility in males, fatty stool, and guild of the fingers and toes. Different individuals may have diverse degrees of symptoms. CF is chiefly inherited as an autosomal recessive gene. It is triggered by mutations in both the copies of the gene for CFTR or cystic fibrosis transmembrane conductance regulator protein. Individuals with a single copy are carriers. Cystic fibrosis transmembrane conductance regulator protein is involved in the production of digestive fluids, mucus, and sweat. When the protein is not functional, secretions otherwise thin become thick. The ailment is mostly diagnosed by genetic testing and sweat test.

Over the last few years, advancements in technology have resulted in a shift in research and development towards treatments that target the fundamental cause of the disease by targeting the CFTR function. Moreover, there is an affinity towards licensing the products, and for that reason alliances are being made by a number of biotechnology and pharmaceutical manufacturers, since the majority of the treatments for cystic fibrosis are developed by smaller manufacturers. The increase in licensing activity along with the rise in the number of new partnerships will encourage the smaller companies to continue their research work thereby giving a positive momentum to the cystic fibrosis market.

In spite of significant advancement in cystic fibrosis therapeutics, individuals suffering from CF face significant unmet needs owing to the deficiency of restorative therapies, inadequate choice of mucolytic treatments, and the unvarying fight alongside severe lung infection that needs the expansion of novel antibiotics. These factors are likely to drive the growth of the cystic fibrosis market during the forecast period.

Cystic fibrosis market Taxonomy

On the basis of therapy type, the global market is classified into:

    • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
    • Protein Transcription Modulators
    • Pancreatic Enzyme Products (PEP)
    • Other therapies

There are many types of antibiotics for CF lung infections such as P. aeruginosa and S. aureus. Nevertheless, excessive use of the drug may lead to resistant strains of the gene. Antibiotics are the most common treatment regime in CF, since they are mainly used to eliminate pathogens in recently infected patients. Antibiotics are used on a long-term basis to avoid the requirement of more serious hospital treatments as a result of their ability to control the infection. The requirement for a more wide range of antibiotics is mirrored in the CF treatment market, with more than a few novel antibiotics in active development phase. This dynamic nature of the treatment for CF will encourage the growth of the global CF market.

High prevalence of genetic diseases including CF will drive the overall cystic fibrosis market

According to Netwellness, a community service provider, 3 to 4% of the babies are born with genetic disorders. This number is poised to rise in the coming years, especially in the emerging economies of Asia pacific such as China and India owing to high birth rate observed in these regions. As the number of cases of CF rises, so will the demand for CF treatment, thereby augmenting the growth of the overall cystic fibrosis market during the forecast period.

On the basis of geography North America held the maximum market share in the cystic fibrosis market globally. Constructive and favorable regulations and policies as well as high availability of sophisticated healthcare facilities and rising approvals of drugs for treating CF are likely to propel the growth of the cystic fibrosis industry in this region.

Some of the key players operating in the global cystic fibrosis market are AbbVie, Inc., Aradigm, Aurora Biosciences, Bayer AG, Demegen, EryDel, Genentech, Inc., InDex Pharmaceuticals, ManRos Therapeutics, Novartis AG, Polydex Pharmaceuticals, and F. Hoffmann-La Roche AG.

Key Developments

  1. Major market players are involved in various business strategies such as partnership and collaboration, in order to gain competitive edge in the market. For instance, in October 2018, AbbVie, Inc., a biopharmaceutical company, partnered with Galapagos NV, for the development and commercialization of cystic fibrosis (CF) program.
  2. Major companies in the global market are focused on various growth strategies such as business and capacity expansion, in order to enhance their market presence. For instance, in June 2018, Vertex Pharmaceuticals, Inc. expanded its San Diego research site that discovered its key cystic fibrosis drugs. The expanded site covers an area of 170,000 square feet, which will boost Vertex’s drug production ability.
  3. Key players in the market are focused on various business strategies such venture capital investment, in order to gain competitive edge in the global market. For instance, in April 2018, Novartis Venture Fund along with Versant Ventures invested US$ 41 million for series B round in cystic fibrosis disease startup Enterprise Therapeutics. The financing will allow Enterprise Therapeutics to push three projects into clinical phase.   


View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo